Rocket Pharma News Today

BioPharma

Rocket Pharma has a pipeline of six gene therapy programs addressing cardiovascular and hematology-based diseases at the genetic level.

The gene therapy programs of Lexeo Therapeutics span rare forms of cardiomyopathy and certain types of Alzheimer’s disease. But Lexeo’s IPO comes as a rival gene therapy developer sues the biotech, claiming its work employs stolen trade secrets.

Rocket Pharmaceuticals, Inc. , a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...

/PRNewswire/ -- Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, announced today three new appointments to...

Rocket Pharma RCKT CEO Gaurav Shah is on a mission to "change the narrative" when it comes to rare diseases. "We are enthusiastic about the potential of [our]…

Jonathan Schwartz, M.D., appointed Chief Gene Therapy Officer to enhance the Company’s focus on strategic application of gene therapy technologies to current and future therapeutic areasMark White, MB.ChB, named Chief Medical Officer; Dr. White brings proven track record in late-stage development and commercializati...

Jonathan Schwartz, M.D., appointed Chief Gene Therapy Officer to enhance the Company’s focus on strategic application of gene therapy technologies to current and future therapeutic areas Mark... | April 4, 2023

“From our first patient until now, all our manufactured drug product that has treated patients has been produced in partnership with...

Feb. 28 is Rare Disease Day. It's meant to observe the more than 400 million people globally — 50% of them children — that are aff...